Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer.
We studied the effect of intraperitoneal recombinant interleukin 2 (rIL-2) on the production of prostacyclin (PGI2) and thromboxane A2 (TxA2) in six patients with metastatic ovarian malignancy. Time-span urine samples collected before and after 17 intraperitoneal instillations of IL-2 (6 x 10(5) IU m-2) were assessed for 2,3-dinor-6-keto-prostaglandin F1 alpha (dinor-6-keto; a metabolite reflecting the in vivo product of PGI2) and 2,3-dinor-thromboxane B2 (dinor-TxB2; a metabolite reflecting the production of TxA2). Analysis was by high-pressure liquid chromatography, followed by radioimmunoassay. Recombinant IL-2 administration was accompanied by a significant rise (85%; P < 0.02) in the output of dinor-6-keto within the first 2 h, and this elevation persisted for up to 6 h. Moreover, output of dinor-TxB2 also rose; this rise (30%) was significant (P < 0.02) 6 h after the instillation. These effects may, in some yet unknown manner, prove significant in the anti-cancer action of rIL-2.
Aitokallio-Tallberg
A
A
Department of Obstetrics and Gynaecology, University of Helsinki, Finland.
Lehtovirta
P
P
Vartiainen
J
J
Ylikorkala
O
O
D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D013928:Thromboxane A2 / Q000096:biosynthesis*
D007376:Interleukin-2; D011994:Recombinant Proteins; D013928:Thromboxane A2; D011464:Epoprostenol